Revive Therapeutics Announces FDA Grants Orphan Drug Designation for Cannabidiol in the Prevention of Ischemia ...
(WorldNews Canada)

TORONTO, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (TSX VENTURE: RVV) (OTCQB: RVVTF) (FSE:31R) (`Revive` or the `Company`), a specialty cannabis company focused on the research, development and commercialization of novel cannabinoid-based products, today announced that the U.S. Food and Drug Administration (`FDA`) has granted orphan drug designation for cannabidiol (`CBD`) in the prevention of ischemia and reperfusion injury (`IRI`) resulting from solid organ transplantation. ......